Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiviral, monoclonal antibodies | 5774 | None |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Clesrovimab is a recombinant human IgG1Îș monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) fusion (F) protein. Clesrovimab inhibits the entry of RSV into host cells by preventing the fusion of the viral envelope with the host cell membrane.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 15, 2026 | EMA | Merck Sharp Dohme Limited | |
| June 9, 2025 | FDA | Merck |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | J06BD10 | ANTIINFECTIVES FOR SYSTEMIC USE IMMUNE SERA AND IMMUNOGLOBULINS IMMUNOGLOBULINS Antiviral monoclonal antibodies |
| FDA MoA | N0000175615 | Fusion Protein Inhibitors |
| FDA EPC | N0000175623 | Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease | indication | 55735004 | DOID:1273 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Fusion glycoprotein F0 | Surface antigen | BINDING AGENT | Kd | 10.15 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| 2429913-18-6 | SECONDARY_CAS_RN |
| CHEMBL4297783 | ChEMBL_ID |
| C000731821 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4044034 | VANDF |
| 4044035 | VANDF |
| C5670521 | UMLSCUI |
| CHEBI:757229 | CHEBI |
| 11857 | INN_ID |
| D12153 | KEGG_DRUG |
| 44159 | MMSL |
| d10287 | MMSL |
| 020138 | NDDF |
| VJO29R4CP9 | UNII |
| 2716802 | RXNORM |
| C000721494 | MESH_SUPPLEMENTAL_RECORD_UI |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ENFLONSIA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-5073 | INJECTION, SOLUTION | 150 mg | INTRAMUSCULAR | BLA | 29 sections |